- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02543294
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
연구 개요
상태
상세 설명
If you agree to take part in this study, the following baseline tests and procedures will be performed on Day 1:
- Your complete medical history will be recorded.
- You will have a physical exam, including measurement of your vital signs (blood pressure, heart rate, and breathing rate).
- You will complete a questionnaire about any symptoms you may be having. The questionnaire should take about 5-10 minutes to complete.
- You will have an echocardiogram (ECHO) and an electrocardiogram (ECG) to check your heart function.
- You will have blood (about 3 tablespoons) drawn for routine tests. If you can become pregnant, part of this blood draw will be used for a pregnancy test. To take part in this study, you must not be pregnant.
- You will be given instructions on how to gradually wean yourself off of your heart failure medication.
- You will be given a machine that you will use to measure your blood pressure at home.
You will be asked to monitor your blood pressure and heart rate at home daily and keep the results in a diary. You should bring your diary to each study visit.
At Month 1:
- You will have a physical exam, including measurement of your vital signs.
- You will complete the questionnaire about any symptoms you may be having.
- You will have blood (about 2 teaspoons) drawn for routine tests.
At Months 2, 4, 6, 12, 18, and 30:
- You will have a physical exam, including measurement of your vital signs.
- You will complete the questionnaire about any symptoms you may be having.
- You will have an ECHO.
- You will have blood (about 2 teaspoons) drawn for routine tests.
At Months 3 and 5, you will have a telephone follow-up with a member of the research team.
Length of Study Participation:
You may continue taking part in the study for up to 6 continuous months with follow-up visits at Months 12, 18, and 30. You will no longer be able to take part if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.
This is an investigational study.
Up to 45 participants will be enrolled in this study. All will take part at MD Anderson.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- University of Texas MD Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Cancer survivors with no evidence of disease for at least 6 months as determined by the oncologist and no longer receiving cancer treatment.
- Prior diagnosis of CILVD with recovered LVEF (i.e. improved to > 50%) for at least 6 months with recommended HF medications (ACE-I or ARB and/or B-blocker).
- Absence of other causes of cardiomyopathy (e.g. ischemia, hypertension, amyloidosis, or hemochromatosis) per chart review of the clinician's documentation
- Documented normal LVEF for at least 6 months after the initiation of recommended HF therapy.
- Age 18 - 80 years. HF clinical guidelines is supported by evidenced-based data from clinical trials which includes individuals up to 80 years of age.
- Residence within the United States.
- Ability to read and write English, because the MD Anderson Symptom Inventory -Heart Failure (MDASI-HF) instrument (Fadol et al., 2008) has been validated in English only.
Exclusion Criteria:
- Participants will be excluded if they have a recurrence that requires anti-cancer treatment.
- Have a documented history of hypertension, coronary artery disease, myocardial infarction, diabetes mellitus, amyloidosis or hemochromatosis.
- Exhibiting HF symptoms (e.g. shortness of breath, edema).
- Pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Anthracycline Treatment Group
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
Electrocardiogram performed at baseline.
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
Telephone follow-up by study staff at months 3 and 5.
|
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
다른 이름들:
Electrocardiogram performed at baseline.
다른 이름들:
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
다른 이름들:
Telephone follow-up by study staff at months 3 and 5.
|
실험적: Herceptin Treatment Group
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
Electrocardiogram performed at baseline.
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
Telephone follow-up by study staff at months 3 and 5.
|
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
다른 이름들:
Electrocardiogram performed at baseline.
다른 이름들:
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
다른 이름들:
Telephone follow-up by study staff at months 3 and 5.
|
실험적: Combination of Treatments Group
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
Electrocardiogram performed at baseline.
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
Telephone follow-up by study staff at months 3 and 5.
|
Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
다른 이름들:
Electrocardiogram performed at baseline.
다른 이름들:
Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
다른 이름들:
Telephone follow-up by study staff at months 3 and 5.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers, Angiotensin Converting Enzyme Inhibitors (ACE-I), or Angiotensin Receptor Blockers (ARB).
기간: A total of 30 months from enrollment date of each participant;
|
A withdrawal failure is defined as a decrease in the LVEF when cardiac medications are discontinued as determined by echocardiogram to LVEF<50% or a decrease by 10% from baseline measurement.
Maintenance of LVEF is defined as LVEF≥50%.
LVEF was assessed at Baseline, Months 2, 4, 6, 12, 18, & 30.
|
A total of 30 months from enrollment date of each participant;
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Risk Factors to Predict Early Decline of Myocardial Function During the Weaning of HF (Heart Failure) Medications.
기간: A total of 30 months from enrollment date of each participant
|
To identify an increased troponin-I that can predict the possibility of HF medication withdrawal failure.
|
A total of 30 months from enrollment date of each participant
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Anecita Fadol, PHD, MSN, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심부전에 대한 임상 시험
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University of... 그리고 다른 협력자들아직 모집하지 않음심부전, 수축기 | 박출률이 감소된 심부전 | 심부전 New York Heart Association Class IV | 심부전 New York Heart Association Class III폴란드
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
University of WashingtonAmerican Heart Association완전한심부전,울혈 | 미토콘드리아 변경 | 심부전 New York Heart Association Class IV미국